Boston Scientific stock falls as cyberattack clouds 2026 guidance

Published on 09/10/2026 at 17:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Boston Scientific stock traded around USD 44.98 on the New York Stock Exchange as of September 8, 2026 after management warned that a recent cyberattack will prevent it from meeting its 2026 guidance. Analysts still project 2026 revenue of about USD 21.37 billion and EPS of USD 3.30, highlighting a gap between near-term disruption and longer-term growth estimates.

Sterile Fertigungslinie für Herzkathetersysteme in einem Medizintechnik-Reinraum in Marlborough MA — Boston Scientific Corp. betreibt sterile Reinraumfertigung für Herzkathetersysteme am Standort Marlborough MA, ISIN US10117L1017, Illustration mit AI erstellt.

Boston Scientific stock (ISIN US10117L1017) was changing hands around USD 44.98 on the New York Stock Exchange as of September 8, 2026, leaving the medical device maker deep below its prior highs after a major cyberattack forced the company to cut its guidance for the third quarter and full-year 2026, as reported at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026.

Cyberattack forces guidance cut and near-term reset

At the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026, Boston Scientific management detailed that an eight-day cyberattack hit all global operations and is likely to prevent the company from meeting its previously issued guidance for the third quarter and full-year 2026, while stressing that global operations have since been restored and the long-term growth strategy remains intact, according to Investing.com.

The company indicated that the cyber incident will weigh particularly on its WATCHMAN left-atrial appendage closure franchise and certain electrophysiology procedures, with management expecting U.S. WATCHMAN procedures to decline in the mid- to high-single-digit percent range in the second half of 2026 and similar market declines in 2027, again based on comments summarized by Investing.com.

Stock near 52-week low despite analyst growth forecasts

The cyberattack and guidance cut have been reflected sharply in the share price: Boston Scientific stock has been trading near its 52-week low of USD 42.20, at around USD 44.96 to USD 44.98 as of September 8, 2026, meaning the shares sit only about USD 2.78 above that low and far below earlier peaks, as highlighted in commentary from Investing.com and options analysis by Trefis.

Analyst estimates nevertheless sketch a more constructive medium-term picture: as of September 10, 2026, Wall Street expects Boston Scientific to deliver revenue of about USD 21.37 billion in fiscal 2026, up roughly 7.97 percent from the prior year, and earnings per share of about USD 3.30, approximately 7.8 percent higher than the USD 3.06 EPS recorded a year earlier, according to consensus data compiled by Yahoo Finance.

Fundamentals and 2027–2028 outlook under scrutiny

While the latest conference comments focus on the disruption from the cyberattack, the underlying business trend remains one of moderate growth: for the current quarter ending September 2026, analysts project revenue of about USD 5.26 billion and EPS of USD 0.81, compared with year-ago EPS of USD 0.75, implying mid-single-digit earnings growth and revenue growth of about 7.41 percent, based on the same Yahoo Finance consensus tables.

Management has cautioned that 2027 will likely be a year of minimal EPS growth, with organic sales expected to increase only about 2 percent to 4 percent, before a planned return to more typical growth rates in 2028 as new product launches and restructuring benefits take hold and as integration of acquisitions such as Penumbra-related assets contributes more strongly, according to strategic commentary quoted by Investing.com.

Next earnings date and valuation signals

Investors will get a more detailed update when Boston Scientific releases its next set of quarterly figures around October 28, 2026, a date referenced in recent coverage of the company’s outlook and financial calendar, including summaries by Investing.com Germany.

Valuation metrics discussed in the Wells Fargo conference analysis suggest that, despite the near-term setback, Boston Scientific trades on a price-earnings ratio of about 18.33 and a PEG ratio near 0.38, levels that some observers view as indicating that the stock may be undervalued relative to its longer-term growth prospects, again based on the data overview cited by Investing.com.

Boston Scientific stock price snapshot

Boston Scientific stock is primarily listed on the New York Stock Exchange under the ticker BSX. Recent price snapshots from September 8, 2026 show the shares around USD 44.98 at the close, with the stock trading close to its 52-week low of USD 42.20 and substantially below prior highs cited in options and valuation commentary, underscoring how strongly the cyberattack and guidance cut have weighed on sentiment. At that level, the price stands roughly 5.6 percent above the 52-week low but far below consensus 12-month analyst targets in the USD 70-plus range cited in various analyst overviews.